^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    12-CK gene signature

    1year
    The prognostic significance of a 12-chemokine tertiary lymphoid structure (TLS) gene signature in uveal melanoma (UM) (AACR 2023)
    M1 macrophages, CD8+ and regulatory T cells were enriched in GEP high patients whereas CD4+ memory T cells and activated dendritic cells were more prevalent in GEP low patients.Conclusion Uveal melanoma patients with a high GEP score had inferior survival and were enriched for inflammatory, angiogenic, and EMT pathways, while patients with a low GEP score were more likely to express prognostically favourable driver mutations (EIF1AX, SF3B1). Our results suggest a variable prognostic role of lymphoid aggregates in the setting of UM compared to other solid tumors, warranting further investigation for their differential underlying mechanisms.
    Tumor mutational burden • Gene Signature
    |
    TMB (Tumor Mutational Burden) • GNAQ (G Protein Subunit Alpha Q) • CD8 (cluster of differentiation 8) • SF3B1 (Splicing Factor 3b Subunit 1) • BAP1 (BRCA1 Associated Protein 1) • IL6 (Interleukin 6) • GNA11 (G Protein Subunit Alpha 11) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL19 (C-C Motif Chemokine Ligand 19) • CCL2 (Chemokine (C-C motif) ligand 2) • GZMB (Granzyme B) • CCL8 (C-C Motif Chemokine Ligand 8) • GZMA (Granzyme A) • IFNA1 (Interferon Alpha 1) • PRF1 (Perforin 1) • CCL18 (C-C Motif Chemokine Ligand 18) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    SF3B1 mutation • BAP1 mutation • 12-CK gene signature
    1year
    Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. (PubMed, Cancers (Basel))
    Moreover, the chemotaxis of CD8T-cells to PAAD cells was significantly increased in vitro with upregulated expression of ERα or ERβ on PAAD cells. To conclude, our study showed a novel correlation between ER expression and TLS development, suggesting that ERs may play a protective role by enhancing anti-tumor immune responses in PAAD.
    Journal
    |
    ER (Estrogen receptor)
    |
    12-CK gene signature
    2years
    A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. (PubMed, Med Oncol)
    The score of the 12-chemokine TLS signature may serve as a pancancer marker of the immune-active phenotype. The 12-chemokine TLS signature showed promise as a predictive and prognostic biomarker for ICB efficacy, especially in melanoma and bladder cancer.
    Journal • Tumor Mutational Burden • Gene Signature • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    12-CK gene signature • TNB-H
    over2years
    Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. (PubMed, Cancer Immunol Immunother)
    This study described a 12-chemokine gene signature for TLS in ccRCC and established TLS clusters that reflected different TME immune status and corresponded to prognosis of ccRCC. We confirmed the dense presence of TILs aggregation and TLS in ccRCC and demonstrated an oncogenic role of CXCL13 expression of ccRCC, which help develop immunotherapies and provide novel insights on the long-term management of ccRCC.
    Journal • IO biomarker
    |
    VEGFA (Vascular endothelial growth factor A) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL19 (C-C Motif Chemokine Ligand 19)
    |
    12-CK gene signature • CXCL13 expression
    over3years
    Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. (PubMed, Sci Rep)
    High TLS scoring predicted favorable prognosis in certain cancer after surgical treatment and improved response to immunotherapy in lung cancer and melanoma. Our findings unraveled the genomic properties associated with TLS formation in different solid tumors and highlighted the prognostic and predictive significance of TLS in surgical treatment and immunotherapy.
    Clinical • Clinical data • Journal • Tumor Mutational Burden • BRCA Biomarker • Pan Tumor
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • KEAP1 (Kelch Like ECH Associated Protein 1) • PBRM1 (Polybromo 1) • SMAD4 (SMAD family member 4) • CASP8 (Caspase 8)
    |
    PBRM1 mutation • 12-CK gene signature